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ABSTRACT:
Deregulation of protein synthesis is a common event in human cancer and a key player 
in translational control is eIF4E. Elevated expression levels of eIF4E promote cancer 
development and progression. Recent findings suggest that eIF4E activity is a key 
determinant of the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK mediated tumorigenic 
activity and targeting eIF4E should have a major impact on these pathways in human 
cancer. The function of eIF4E is modulated through phosphorylation of a conserved 
serine (Ser209) by Mnk1 and Mnk2 downstream of ERK. While the phosphorylation 
event is necessary for oncogenic transformation, it seems to be dispensable for normal 
development. Hence, pharmacologic Mnk inhibitors may provide non-toxic and effective 
anti-cancer strategy. Strong circumstantial evidence indicates that Mnk inhibition 
presents attractive therapeutic potential, but the lack of selective Mnk inhibitors 
has so far confounded pharmacological target validation and clinical development. 
INTRODUCTION
Mechanism-based targeted cancer therapy represents 
the remarkable progress of the decades’ research into 
mechanisms of cancer pathogenesis. Most cancer drugs 
developed  to  date  have  been  directed  toward  specific 
molecular targets that are involved in one way or another 
in enabling particular capabilities of tumour growth and 
progression. Such specificity of action presents inhibitory 
activity against a target resulting in a clinical response 
with less of target toxicity. However, the clinical response 
is often followed by relapses. One interpretation is that 
a targeted therapeutic agent inhibiting a single target or 
pathway in a tumour may not be able completely to shut 
off tumorigenic capabilities due to a partially redundant 
network, allowing some cancer cells to survive or adapt 
to the selective pressure imposed by the therapy and 
eventually re-establish oncogenic functionality [1]. On 
the other hand, some multi-targeted inhibitors have 
contributed to the effectiveness for cancer treatment [2]. 
For example, Sorafenib has demonstrated an excellent 
clinical outcome and is approved for the treatment of 
patients with renal cell carcinoma and hepatocellular 
carcinoma. This has been attributed to the broad specificity 
of Sorafenib, which inhibits other targets besides Raf, 
including VEGFR, Flt-3, PDGFR and others. Co-targeting 
the key components of several signalling pathways 
simultaneously has been proposed as a more effective drug 
development strategy [3].
Eukaryotic initiation factor 4E (eIF4E) is a general 
translation factor, but it has the potential to enhance 
preferentially the translation of messenger RNAs 
(mRNAs) that lead to production of a malignancy-
associated proteins. This selectivity may relate to an 
increased requirement for eIF4E and its binding partners 
for the translation of mRNAs containing extensive 
secondary structure in their 5’-untranslated regions (5’-
UTRs) [4-6]. These mRNAs include those encoding 
certain proteins that control cell cycle progression and 
tumourigenesis such as c-Myc and cyclin D1; growth 
factors (the basic fibroblast growth factor 2, FGF2 and 
vascular endothelial growth factor, VEGF), powerful 
promoters of cell growth and angiogenesis, as well as the 
anti-apoptotic protein Mcl-1 [6-12]. Under normal cellular 
conditions the translation of these malignancy-associated 
mRNAs is suppressed as the availability of active eIF4E 
is limited; however, their levels can increase when eIF4E 
is over-expressed or hyperactivated. 
Elevated levels of eIF4E have been found in many 
types of tumours and cancer cell lines including cancers of 
the colon, breast, bladder, lung, prostate, gastrointestinal 
tract, head and neck, Hodgkin’s lymphomas and Oncotarget 2012; 3:  118-131 119 www.impactjournals.com/oncotarget
neuroblastomas, but not in typical benign lesions [8, 10, 
13-20]. A role for eIF4E as a prognostic marker has also 
been suggested for certain cancers and the involvement 
of eIF4E in metastasis has been considered [8, 10, 12, 
21, 22]. Further evidence supporting a role for eIF4E 
in malignancy has been provided by studies where 
expression of antisense RNA to eIF4E in HeLa cells 
suppressed proliferation and altered cellular morphology 
[23]. Antisense RNA-mediated reduction of eIF4E in 
breast, head and neck cancer cells was also shown to 
suppress tumour formation, growth and metastasis [24-
29]. Elevated eIF4E accelerated lymphomagenesis and 
promoted drug resistance in a transgenic mouse model 
[30]. The studies have provided proof of concept that the 
deregulation of eIF4E-mediated translation initiation is 
an important step in oncogenic transformation and may 
contribute to tumour maintenance. 
Translation is tightly regulated. Initiation of cap-
dependent translation is thought to depend on the assembly 
of eIF4F, an initiation factor complex including eIF4E, 
the scaffold protein eIF4G, and the RNA helicase eIF4A 
[31-33]. Because eIF4E is the only one of these proteins 
that binds directly to the mRNA cap structure, it is the 
key factor for the assembly of eIF4F at the 5’ cap (Figure 
1) [32, 34]. The scaffold protein, eIF4G, also recruits the 
40S ribosomal subunit to the mRNA via its interaction 
with eIF3 and binds eIF4B, a protein that aids the RNA-
helicase function of eIF4A, thus facilitating the translation 
of mRNAs that contain structured 5’-UTRs (Figure 1). 
The availability of eIF4E as part of the eIF4F complex 
is a limiting factor in controlling the rate of translation, 
and therefore eIF4E is an important regulator of mRNA 
translation. As described below, the availability of eIF4E 
is controlled by eIF4E-binding proteins (4E-BPs) which 
can interact with eIF4E and prevent it binding eIF4G. 
4E-BPs undergo phosphorylation resulting in their release 
from eIF4E, allowing it to form eIF4F complexes.
Regulation of eIF4E activity forms a node of 
convergence of the PI3K/Akt/mTOR and Ras/Raf/
MAPK signalling pathways. A schematic overview of the 
signalling network is presented in Figure 2 [4, 32, 35]. 
The PI3K (phosphoinositide 3-kinase)/PTEN (phosphatase 
and tensin homologue deleted on chromosome ten)/Akt/
mTOR (mammalian target of rapamycin) pathway is 
often involved in tumorigenesis and in sensitivity and 
resistance to cancer therapy. Deregulated signalling 
through the PI3K/PTEN/Akt/mTOR pathway is often 
the result of genetic alterations in critical components 
of this pathway and/or mutations at upstream growth 
factor receptors or signalling components. Activated 
by extracellular growth factors, mitogens, cytokines, 
receptors, etc., PI3K initiates a cascade of events. PDK1 
activates Akt, which in turn phosphorylates and inactivates 
the tumour suppressor complex comprising TSC1 and 
2 (tuberous sclerosis complex 1/2), resulting in the 
activation of mTORC1 (target of rapamycin complex 1) 
by Rheb-GTP. Activation of PDK1 and Akt by PI3Ks is 
negatively regulated by PTEN [2, 36]. PTEN is a critical 
tumour suppressor gene and is often mutated or silenced 
in human cancers [37-39]. Its loss results in activation of 
Akt and increases downstream mTORC1 signalling. The 
involvement of mTOR complex1 (mTORC1) in neoplastic 
Figure 1: mRNA recruitment during translation initiation. (i) The eIF4F complex including eIF4E, eIF4A and eIF4G is recruited 
to the mRNA via an interaction between eIF4E and the 5’-cap of the mRNA, which includes a 7-methylguanosine moiety; (ii) eIF4B 
binds to eIF4G and enhances the helicase activity of eIF4A; (iii) secondary structure (stem loops) in the 5’-untranslated region of the 
mRNA, which can inhibit translation initiation, are ‘unwound’ by eIF4A/eIF4B; (iv) the 40S ribosomal subunit is recruited to mRNA via 
an interaction between eIF4G and eIF3. Together with other translation factors, the 40S subunit then locates the start codon (‘AUG’) via 
‘scanning’. The recruitment of the 40S subunit likely occurs earlier in the process than is depicted here.
Figure 1.  mRNA recruitment during translation initiation.Oncotarget 2012; 3:  118-131 120 www.impactjournals.com/oncotarget
transformation appears to depend on its regulatory role 
toward the eIF4F complex; overexpression of eIF4E 
can confer resistance to rapamycin [30]. mTORC1 
regulates the eIF4F complex assembly that is critical for 
the translation of mRNAs associated with cell growth, 
prevention of apoptosis and transformation. mTORC1 
achieves this by phosphorylation and inactivation of 
4E-BPs and the subsequent dissociation of 4E-BPs from 
eIF4E (Figure 2). This then enables eIF4E to interact with 
the scaffold protein eIF4G permitting assembly of the 
eIF4F complex for the translation of structured mRNAs 
[34, 40, 41]. mTORC1 also promotes activation of the 
translational activator, S6K, which phosphorylates the 
ribosomal protein S6 and other substrates, including eIF4B 
[42]. mTORC1 signalling is inhibited by rapamycin and 
its analogues (rapalogs), although these compounds act 
allosterically, rather than directly inhibiting mTOR kinase 
activity. Rapamycin and its analogues have been shown to 
be cytostatic, not cytotoxic, to leukemic and other cancer 
cells. 
Given the importance of the PI3K/Akt/mTOR 
pathway in regulating mRNA translation of genes that 
encode for pro-oncogenic proteins and activated mTORC1 
signalling in a high proportion of cancers, these kinases 
have been actively pursued as oncology drug targets [43, 
44]. A number of pharmacological inhibitors have been 
identified, some of which have reached advanced clinical 
stages [2, 45]. However, it has recently become clear that 
the mTOR pathway participates in a complicated feedback 
loop that can impair activation of Akt [30, 46, 47]. It has 
been shown that prolonged treatment of cancer cells or 
patients with mTOR inhibitors causes elevated PI3K 
activity that leads to phosphorylation of Akt and eIF4E, 
and promotes cancer cell survival [48, 49]. eIF4E, acting 
downstream of Akt and mTOR, recapitulates Akt’s action 
in tumourigenesis and drug resistance, and Akt signalling 
via eIF4E is an important mechanism of oncogenesis 
and drug resistance in vivo [30]. For these reasons, dual 
targeting of both Akt and mTOR, or directly inhibiting 
eIF4E activity, have been proposed as treatments for 
cancer [2, 30, 50, 51]. 
In addition to the PI3K/Akt/mTOR pathway, eIF4E 
is also the target of the Ras/Raf/MAP signalling cascade 
which is activated by growth factors and for the stress-
activated p38 MAP kinase pathway (Figure 2). Erk1/2 and 
p38 then phosphorylate MAP kinase-interacting kinase 
Figure 2: The regulation of eIF4E forms a node of convergence of two intracellular signalling pathways. The Ras/Raf/
ERK pathway culminates in the activation of the Mnks (especially Mnk1a). Mnk1a can also be activated by p38 MAPK downstream of 
cytokines or stressful stimuli. Mnk binds to eIF4G and phosphorylates eIF4E within the eIF4F complex.  The functional consequences of 
phosphorylation of eIF4E are unclear but are believed to favour the translation of certain mRNAs. Stimulation of PI3K, e.g., by growth 
factors, initiates a cascade of events: PDK1 activates AKT which phosphorylates TSC2, thereby inactivating the TSC1/TSC2 complex. 
Rheb, the small G protein, is no longer inhibited by the GAP (GTPase-activating protein) activity of TSC2 and the resulting Rheb-GTP 
activates mTORC1 via unknown mechanisms. mTORC1 promotes the activation of the translational activator S6K and the hierarchical 
phosphorylation of 4E-BP. Hyperphosphorylated 4E-BP is released from eIF4E, thereby allowing eIF4E to bind to eIF4G. Activated S6K 
phosphorylates eIF4B and PDCD4, effects which promote the helicase activity of eIF4A. The dashed lines indicate possible links.
Figure 2. The regulation of eIF4E forms a node of convergence of two intracellular signalling 
pathways.Oncotarget 2012; 3:  118-131 121 www.impactjournals.com/oncotarget
1 (Mnk1) and Mnk2. The Erk pathway is also activated 
in  many  cancers,  reflecting,  for  example,  activating 
mutations in Ras (found in around 20% of tumour cells) or 
loss of function of the Ras GTPase-activator protein NF1. 
Mnk1 and Mnk2 specifically phosphorylate serine 
209 (Ser209) of eIF4E within the eIF4F complex, by virtue 
of the interaction between eIF4E and the Mnks, which 
serves to recruit Mnks to act on eIF4E [49, 52]. Mnk1 and 
Mnk2 knock-out or knock-in mice, in which Ser209 was 
replaced by alanine, showed no eIF4E phosphorylation 
and  significantly  attenuated  tumour  growth  [53-55]. 
Significantly, while Mnk activity is necessary for eIF4E-
mediated oncogenic transformation, it is dispensable for 
normal development [53]. Pharmacologically inhibiting 
Mnks may, therefore, present an attractive therapeutic 
strategy for cancer. Despite increased understanding of 
structure and function of the Mnks, little progress has been 
made with Mnk-targeted drug discovery. In this review we 
intend to update the progress made in validating the Mnks 
as a potential therapeutic target and to provide an insight 
into binding models of selected prototype inhibitors in 
complex with the Mnks. The rationales and inhibitor 
design principles will be discussed.
STRUCTURE AND FUNCTIONS OF MNKS 
Mnk1 and Mnk2 are threonine /serine protein kinases 
and were originally discovered as the result of screening 
for substrate s or binding partners for Erk [56, 57]. So 
far four human Mnk isoforms (Mnk1a, 2a, 1b and 2b) 
and two mouse Mnk isoforms (Mnk1and 2) have been 
reported [56-60]. Sequence alignment analysis reveals 
that all four isoforms have a nuclear localization signal 
(NLS) and an eIF4G-binding site in their N-terminal 
regions (Figure 3A) which, respectively, allow the 
kinases to enter the nucleus and to phosphorylate eIF4E 
efficiently. The central catalytic domains of the pairs of 
isoforms Mnk1a/b and Mnk2a/b are identical and closely 
homologous between Mnk1 and Mnk2 proteins [61]. 
The main structural differences lie within the C-terminal 
domain (Figure 3B). The C-terminal regions of Mnk1a 
and Mnk2a contain a MAPK-binding site, and thus can be 
phosphorylated and activated by Erk and p38 MAPK [49, 
56]. Their short isoforms, Mnk1b and 2b, however, lack 
this domain and are poor substrates for Erk or p38 [58-
61]. At least two threonine residues (Thr209 and Thr214 
in human Mnks indicated in Fig. 3A) in this region are 
phosphorylated by MAPKs, and their replacement with 
alanine results in inactive kinases [56, 60, 62]. The 
threonine residues in Mnks correspond to the residues 
in MK2/3 (MAPK-activated protein kinases), which 
can also be phosphorylated by p38, suggesting a similar 
activation mechanism [63]. Furthermore, Mnk1a localises 
predominantly to the cytoplasm, whereas a significant 
proportion of the alternative Mnk variants is present 
within the nucleus. One possible explanation for this is 
that, although maintaining the NLS, these isoforms lack 
the C-terminal nuclear export sequence (NES) found 
in Mnk1a, impairing their exit from the nucleus to the 
Figure 3: Schematic representation of the structure of splice variants of human Mnk1 and Mnk2. (A) Sequence alignment 
of kinase domains inserts the DFD motif (shaded box); Thr209/Thr214, the MAPK phosphorylation sites (P); and the kinase inserts (shaded 
box). (B) The layout indicates the arrangement of the known functional domains (as labelled). NLS: nuclear localization signal; NES: 
nuclear export signal; eIF4G, the scaffolding protein of the translation initiation complex eIF4F that binds Mnk1 and Mnk2. Oncotarget 2012; 3:  118-131 122 www.impactjournals.com/oncotarget
cytoplasm [58, 62, 64, 65].While the activity of Mnk1a 
is tightly regulated by Erk and p38 MAP kinase, Mnk2a 
shows high basal activity, and Mnk1b and Mnk2b show, 
respectively, quite high and low activity, which appears to 
be unregulated, likely reflecting their lack of binding sites 
for Erk/p38 MAPK [65].
eIF4E is the only thoroughly-characterised 
physiological substrate for Mnks, although other 
substrates have been identified (reviewed in [65]), and 
expression of activated Mnks increases the cellular level 
of phosphorylated eIF4E in the cells [56, 66]. Both Mnk1 
and Mnk2 specifically phosphorylate eIF4E at Ser209, 
and Ser209 is the only phosphorylation site in eIF4E 
[52, 55, 57, 67]. Mnk and eIF4E interact with eIF4G 
bringing them into physical proximity to facilitate eIF4E 
phosphorylation (Figure 2). The biological significance of 
eIF4E phosphorylation and its effect on translation is not 
completely understood. Biophysical studies indicate that 
phosphorylation of eIF4E actually decreases its affinity 
for the cap of mRNA, which play a role in facilitating 
scanning or permitting the transfer of eIF4E from mRNAs 
that are already undergoing translation to other mRNAs 
whose translation is subsequently promoted [49, 52].
In addition to its role in translation, eIF4E also 
appears to mediate the export of a set of mRNAs from 
the nucleus to the cytoplasm; these include mRNAs for 
a number of proteins involved in cell cycle progression 
or cell survival [68]. Phosphorylation of eIF4E by Mnks 
may also be important for its role in the export of some 
mRNAs, e.g., cyclin D [69] and hdm2 [70], providing a 
further mechanism by which phosphorylation of eIF4E 
may promote tumourigenesis.
Drosophila expressing a mutant eIF4E in which 
Ser251, the residue which corresponds to the Ser209 of 
mammalian eIF4E is mutated to alanine, show reduced 
viability [71]. By contrast, mice with deletions in both 
Mnk1 and Mnk2 develop normally without detectable 
eIF4E phosphorylation [30]. Recent studies confirmed 
that phosphorylation of eIF4E at the Ser209 by Mnk is 
essential for eIF4E’s ability to promote tumourigenesis 
[72], while it is dispensable in normal tissue [21, 35, 54, 
55, 72].
In an elegant study, a mouse model in which 
lymphomas generated from Eµ-Myc transgenic HSCs 
(hematopoietic stem cells) were transfected with wild-
type eIF4E and eIF4E-mutants, was used to investigate 
their effects on oncogenicity [72]. Wild-type eIF4E greatly 
enhanced Myc-mediated lymphomagenesis compared 
to animals expressing eIF4E Trp56Ala, a mutant with 
defective cap-binding ability, implying a crucial oncogenic 
function for eIF4E. Similarly, mice reconstituted with cells 
carrying the Ser209Ala mutant were defective in tumour 
development to a similar extent to the Trp56Ala mice, 
suggesting that phosphorylation of Ser209 is important 
for eIF4E-mediated tumourigenesis. Conversely, activated 
Mnk1 promoted the onset of tumour development in a 
similar manner to eIF4E. Mnk1- and eIF4E-expressing 
lymphomas showed low levels of apoptosis compared to 
control tumours. This was attributed to the ability of eIF4E 
or Mnk1 to enhance the expression of the anti-apoptotic 
protein Mcl-1, and it was shown that Mnk1-mediated 
phosphorylation of eIF4E at Ser209 correlated with the 
level of Mcl-1 expression [72]. 
Further investigation of the link between Mnk1/2 and 
tumourigenesis driven by loss of PTEN demonstrated that 
Mnk1/2-double knock-out tPTEN−/− mice (T-cell-specific 
PTEN conditional knockout mice) showed attenuated 
tumour growth compared to the parental tPTEN−/−mice 
[54]. Phosphorylation of eIF4E was greatly enhanced in 
lymphomas from tPTEN−/− mice compared with lymphoid 
tissues of wild-type mice, but was abolished in lymphomas 
of tPten−/−; Mnk1/2-double knock-out mice, confirming 
that Mnk1 and Mnk2 kinase activity are essential for 
eIF4E phosphorylation in transformed cells. This was 
consistent with the high levels of Mnk1 and eIF4E 
phosphorylation exhibited by human glioma U87MG 
cells bearing an inactivating PTEN mutation. Conversely, 
U87MG cells in which Mnk1 had been knocked down 
by shRNA showed substantially reduced levels of 
phosphorylated eIF4E and markedly decreased tumour 
formation [54]. A complementary study was carried out 
using knock-in mice, in which eIF4E Ser209 was mutated 
to alanine [55]. Mouse embryonic fibroblasts isolated from 
eIF4E Ser209A mice lacked eIF4E phosphorylation and 
Figure 4: The chemical structures of MNK inhibitors and derivative.
Cercosporamide
O
O O HO
OH
O
NH2 HO
N
H
N
N
O
O
O
O
N
N N
H
N
HN NH2
CGP052088
CGP57380
F
N
N N
N
HN NH2
F
Me
SHN-093
 
Figure 4: The chemical structures of MNK inhibitors and derivative. 
 
 
 
 
 
 
 
 
 
 
 
 
 Oncotarget 2012; 3:  118-131 123 www.impactjournals.com/oncotarget
displayed a marked resistance to transformation in vivo. 
The study failed to reveal any obvious phenotype in Mnk 
knock-in mice; however, cells derived from these mice are 
resistant to Ras-activated oncogenic transformation. All 
these studies provide the proof of concept that inhibition 
of Mnk activity may be an effective therapeutic strategy 
for selectively targeting cancer cells while sparing normal 
cells.
Several studies have shown that treatment of some 
types of cancer cells with rapamycin (or its analogs) 
actually increases the phosphorylation of eIF4E [51] which 
may promote tumourigenesis. This seems surprising, given 
that rapamycin should enhance the association of eIF4E 
with 4E-BPs and thus interfere with recruitment of eIF4E 
to the eIF4G/Mnk complex. However, rapamycin fails to 
inhibit 4E-BP1 phosphorylation in a number of cell types 
[73, 74]. Development of Mnk inhibitors may be of value 
in preventing these undesirable consequences of inhibiting 
mTORC1 using rapalogs.
KNOWN MNK INHIBITORS
Despite increased understanding of Mnk structure 
and function, little progress has been made with the 
Figure 5: Ribbon plot (brown) displaying the crystal structures of Mnk kinase domain. Residues around the DFD motif in 
either the DFG/D-IN or -OUT conformations are displayed as green sticks and the residues in the ATP-hinge region are shown as orange 
sticks. The gate keeper residues are indicated by red sticks. (A) The DFG/D-OUT conformation of wild-type Mnk2-KR is indicated with 
Phe227 and Asp228 poking into the ATP binding cleft (PDB 2AC3). The DFG/D-OUT conformation not only positions Phe227 and Asp228 
in the ATP binding cleft, but also obstructs access to this cleft from the front. (B) In the Mnk2-KRD228G (Asp228Gly mutant), the DFG 
motif is found in both DFD/G-IN and DFD/G-OUT conformation and Phe227 flaps in/out shown by the green curly arrow (PDB 2AC5). (C) 
The DFG/D-OUT conformation of wild-type Mnk1-KR (PDB 2HW6), and (D) the structure of Mnk2-KRD228G–Staurosporine complex 
(PDB 2HW7). Staurosporine is displayed as a pink stick structure. The dashed lines indicate hydrogen bonds. 
Figure 5. Ribbon plot (brown) displaying the crystal structures of Mnk kinase domain.Oncotarget 2012; 3:  118-131 124 www.impactjournals.com/oncotarget
discovery of pharmacological Mnk inhibitors. So far three 
Mnk inhibitors have been reported: CGP052088 [75], 
CGP57380 [76-79], and Cercosporamide [80] (Figure 
4). These compounds have mainly served as chemical 
biological tools for Mnk target validation. 
CGP052088 is a derivative of staurosporine, a broad-
spectrum kinase inhibitor. It inhibits Mnk1 with an IC50 
value of 70 nM in biochemical assays and is cytotoxic 
with a GI50 value of 4.5 µM in a 24h-MTT proliferation 
assay [75]. CGP052088 blocked phosphorylation of eIF4E 
at Ser209 in human embryonic kidney 293 cells within 
45 minutes. Interestingly, a closely related stereoisomer, 
CGP052428, failed to show a similar action. This was 
attributed to CGP052428 lacking Mnk1 inhibitory activity, 
although it has the same cellular cytotoxicity compared as 
CGP052088. Both compounds likely affect other enzymes 
in addition to the Mnks. 
CGP57380 [81], 4-amino-3-(p-fluorophenylamino)
pyrazolo[3,4-d]pyrimidine (Figure 4), was found to be a 
potent Mnk1 and Mnk2 inhibitor. It inhibits Mnk1 and 
Mnk2 with IC50 values of 0.7 and 0.8 µM respectively 
in an in vitro assay conducted with relatively low 
concentrations of ATP [65]. The compound also targets 
CK1 with similar potency as Mnk1 and shows potently 
inhibitory activity against other kinases including Aurora 
B, DYRK, SGK, BRSK2, and Lck within a low µM IC50 
range [82]. Detailed cellular mechanistic studies revealed 
that CGP57380 substantially reduced eIF4G in the eIF4F 
complex and drastically inhibited eIF4E phosphorylation 
[83, 84]. It also decreased the expression levels of 
oncoprotein c-Myc and anti-apoptotic protein Mcl-1 
[84]. Treatment of Jurkat T-cells with 40μM CGP57380 
showed that eIF4E phosphorylation was completely 
blocked and TNFα production was inhibited by up to 
75%  [77],  suggesting  that  Mnk  may  regulate  TNFα 
mainly by modulating the translational efficiency of its 
mRNA. Interestingly, SHN-093, a methylated analogue 
of CGP57380 (Figure 4), was completely inactive against 
Figure 6: The binding models of Mnk inhibitors. (A) Interactions of CGP57380 (green) within the ATP binding domain, and (B) 
schematic presentation of the corresponding interactions. (C) Interactions of cercosporamide (green) within the ATP binding domain, and 
(D) schematic presentation of the corresponding interactions. The DFD motif: pink sticks; Hinge region: orange sticks; Gate keeper: red 
sticks; Inhibitors: green sticks. Hydrogen bonds: dashed lines; Hydrophobic region I: shaded pink; Hydrophobic region II: shaded light 
blue; Allosteric pocket: shaded light beige. The likely binding posts were generated by Autodock 4.0 (http://w3.to/autodock). The structure 
of the Mnk2-KRD228G–Staurosporine complex (PDB2HW7) was used as the initial template. The dimensions of the active site box were 
chosen to be large enough to encompass the entire ATP binding pocket and allosteric site. Docking calculations were carried out using the 
Lamarckian genetic algorithm (LGA). A maximum number of 2,500,000 energy evaluations were used. Each docking experiment consisted 
of 100 independent runs.Oncotarget 2012; 3:  118-131 125 www.impactjournals.com/oncotarget
Mnk1/2 in both biochemical and cell-based assays, 
indicating the importance of 1-NH of pyrazolo moiety 
for Mnk inhibition. A binding model for CGP57380 
to Mnk2 has been proposed (see below section). 
The model may offer a starting point for a medicinal 
chemistry optimisation program and the structure-activity 
relationship established would allow better understanding 
of the binding of inhibitors in the Mnk active site. 
Isolated from Cercosporidium henningsii, 
cercosporamide  was  originally  identified  as  a  host-
selective phytotoxin and broad spectrum antifungal 
agent [85]. Cercosporamide was later shown to inhibit 
a cell wall integrity pathway mediated through PKC1 
(IC50 < 50 nM) [86, 87]. It was only recently discovered 
that cerosporamide is also a potent Mnk inhibitor, 
inhibiting Mnk1 and Mnk2 with an IC50 of 0.116 and 
0.11 µM respectively [80]. However, it also inhibits 
a  number  of  other  kinases,  including  Jak3,  GSK3β, 
ALK4 and Pim1, all in the low µM potency range [80]. 
Cercosporamide was the first Mnk inhibitor to show in 
vivo  anti-tumour  efficacy  in  human  xenograft  tumour 
models. Oral administration of a single dose of 20 mg/kg 
cercosporamide was able to significantly inhibit tumour 
growth in HCT116 colon carcinoma xenograft model. 
In a B16 melanoma mouse model cercosporamide also 
suppressed pulmonary metastases when dosed at 10 mg/
kg (twice daily) or 20 mg/kg (daily) for 12 days, with 
minimal toxicity. Cercosporamide effectively blocked 
eIF4E phosphorylation at Ser209, suppressing cancer cell 
proliferation and colonization and leading to induction of 
apoptosis. As cerosporamide targets multiple kinases, it 
is important to dissect its exact biological mechanism of 
action. 
DESIGN OF SELECTIVE MNK INHIBITORS
Mnks apparently have specific functions in cancer 
cells, which are redundant in the normal cells. These 
may be mediated through eIF4E’s roles in mRNA 
translation and export, although it cannot be excluded 
that additional Mnk substrates are involved. It follows 
that in order to maximise the therapeutic margin of Mnk 
inhibitors, molecules with high selectivity for Mnk over 
other kinases are required. Structural studies reveal that 
the Mnk kinase domain is homologous to the family of 
Ca2+/calmodulin-modulated protein kinases (CaMK) [88]. 
However Mnk1/2 possess two distinct features: (1) their 
kinase domains contain a DFD motif (Asp191-Phe192-
Asp193 in human Mnk1 and Asp226-Phe227-Asp228 in 
human Mnk2) which replaces the DFG (Asp-Phe-Gly) 
motif found in other protein kinases [61, 89, 90]; (2) the 
catalytic domain contains Mnk specific inserts (EVFTD in 
Mnk1 and EAFSE in Mnk2) not observed in other kinases. 
It has been suggested that the DFD motif makes it more 
difficult for ATP to access to the binding domain [61, 
89]. Indeed, three-dimensional crystal structure analyses 
of the kinase regions of Mnk1 (Mnk1-KR) and Mnk2 
(Mnk2-KR), as shown in Figure 5A and 5B, indicates that 
the DFD motif is rotated by 180° when compared to the 
DFG motif of other protein kinases. The Phe227 in the 
Mnk2-KR inserts into the ATP binding pocket, preventing 
ATP from entering this binding site (Figure 5A). This 
non-canonical arrangement of the DFD motif is referred 
to as the “DFG/D-OUT” conformation, as compared to 
the standard “DFG/D-IN” conformation found in other 
active kinases. Interestingly, the structure of Mnk2-KR 
(D228G), in which Asp228 was replaced with a glycine 
residue, showed that it could now adopt both DFG/D-IN 
Figure 7: The interactions between Mnk2 and the proposed inhibitor which not only acts as ATP competitor but also 
interacts with the DFD motif. (A) 3D view of the interactions. The inhibitor is shown in green sticks. Residues around the inhibitor are 
shown in orange sticks. Red dashed lines indicated the hydrogen bond interactions or electrostatic interactions. (B) Schematic presentation 
of the corresponding interactions. Hydrogen bonds: dashed lines; Hydrophobic region I: shaded pink; Hydrophobic region II: shaded light 
blue; Allosteric pocket: shaded light beige. The binding post was generated by the following procedures: the DFD/G-IN structure of the 
Mnk2 (PDB 2AC3) was used as the initial template; the conformation of Phe227 was modified to make the ATP binding pocket accessible 
for the inhibitor.
Figure 7: The interactions between Mnk2 and the proposed inhibitor which not only acts as 
ATP competitor but also interacts with the DFD motif.
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and DFG/D-OUT conformations (Figure 5B). As shown in 
Figure 5C, the Mnk1-KR shows similar structural features 
to Mnk2-KR; however, the N-terminal lobe of Mnk2-KR 
is tilted by approximately 10 degrees, making the kinase 
binding pocket slightly more open to accommodate ATP 
or a small molecule inhibitor compared to Mnk1-KR. As 
the DFG/D-OUT conformation of Mnk2 is specific to the 
inhibitor-free protein kinase, Mnks are architecturally 
distinct from most other protein kinases, a feature 
which can be exploited for design of highly selective 
Mnk inhibitors. Analysis of the co-crystal structure of 
staurosporine in Mnk2-KR (D228G) [89] revealed that 
staurosporine binds in the canonical ATP active site in a 
fashion similar to its known binding mode in other protein 
kinases. The polycyclic ring system of staurosporine is 
sandwiched between the N-terminal and C-terminal lobes 
(Figure 5D). The 1-NH and 5-O atoms of staurosporine 
form hydrogen bonds to the backbone residues of Glu160 
and Met162 in the hinge region (Figure 5D). The structural 
information is invaluable for the structure-based design of 
novel Mnk inhibitors. 
The majority of small-molecule kinase inhibitors 
developed so far act as ATP competitors targeting the 
ATP binding site, with their respective kinases adopting 
an identical conformation to that used to bind ATP (the 
active conformation). These inhibitors are sometimes 
referred as type I kinase inhibitors [91]. The chemical 
scaffold of ATP-competitive inhibitors or type I inhibitors 
usually consists of planar heterocyclic systems that act 
as mimetics for the adenine moiety of ATP. They always 
contain characteristic adjacent hydrogen-bond-donor and 
-acceptor groups in the hinge region, the segment that 
connects the N- and C-terminal kinase domains, as well as 
hydrophobic functions. Many ATP competitive inhibitors 
have been successfully developed as therapeutics. 
However, due to the highly conserved structure of the 
ATP binding domain in most kinases, these inhibitors 
often suffer from cross-reactivity with other kinases, 
resulting in poor safety and sometimes severe side effects. 
Nevertheless a number of ATP competitive inhibitors 
have  achieved  good  selectivity  profiles  by  exploiting 
interactions with the non-conserved hydrophobic regions, 
where ATP binding is not involved, as well as interaction 
with the so-called ‘gatekeeper’ residue [92-95].
An alternative strategy for inhibitor design involves 
recognition of both the ATP binding cleft and the adjacent 
hydrophobic pocket created by the kinase activation 
loop. The activation loop is important in the regulation 
of kinase activity and in most protein kinases it is marked 
by conserved DFG and APE motifs at the start and end 
of the loop. Such inhibitors (sometimes termed type II 
inhibitors) are designed to make contact with residues of 
the hydrophobic pocket, which typically adopt the DFG-
OUT conformation of an inactivated kinase. This unique 
hydrophobic pocket is also referred as an “allosteric site” 
[96]. As this binding site is less conserved among kinases 
than the ATP site, an inhibitor targeting this region can in 
principle achieve relatively high specificity. Indeed, such 
inhibitors, including imatinib and nilotinib, exhibit fewer 
side effects and good safety profiles in the clinic [91]. 
The distinctive features of the DFD motif offer a 
unique opportunity for the discovery of highly selective 
Mnk inhibitors. To illustrate the structure-guided design 
approach involved, we performed in silico docking 
experiments for the Mnk inhibitors CGP57380 and 
cercosporamide. As the Phe227 residue in the DFD-
OUT conformation projects into the ATP binding pocket 
to exclude the ATP or ligand from entering the binding 
site, experimental docking is a challenging task. For 
this reason, we used Mnk2 DFD-IN structure instead. 
Modelling studies of CGP57380 and cercosporamide, 
as shown in Figure 6, indicate that the overall binding 
modes of both inhibitors are very similar to that of 
staurosporine (Figure 5D). CGP57380 occupies the 
ATP-binding cleft between the two lobes of Mnk subunit 
(Figure 6A and 6B). The pyrazolo[3,4-d]pyrimidine 
moiety occupies the adenine subsite of the ATP-binding 
pocket, while the 4-fluoroaniline portion projects into the 
hydrophobic region II. The 1-NH, 2-N and 3-NH groups 
of pyrazolo[3,4-d]pyrimidine system form hydrogen-
bonds with the backbone residues of Glu160, Lys161, 
and Met162 at the hinge region of Mnk2. Replacement 
of 1-NH with 1-NMe group would abolish the hydrogen-
bond to Glu160, perhaps explaining why SHN-093 has 
significantly reduced Mnk inhibitory activity compared 
to CGP57380 [65]. The docking experiments also 
suggest that extension of the pyrazolo[3,4-d]pyrimidine 
heterocyclic scaffold, or introduction of an additional 
functional system at the 4-NH position, could generate 
hydrogen-bonds as well as hydrophobic interactions with 
the residues of the DFD motif. This should improve the 
potency and selectivity compared to CGP57380. 
Cercosporamide exhibits a similar binding mode to 
CGP57380 (Figure 6C and 6D). It recognizes the ATP-
binding domain through the characteristic hydrogen-
bonding network, again involving the hinge region 
residues Glu160, Lys161, and Met162, whose backbone 
amide NH and carbonyl functions form hydrogen bonds 
with the 3-OH and 4-carboxamide of the phenyl portion 
of cercosporamide. The DFD motif residues would be 
an obvious candidate for full exploitation in order to 
achieve the optimal hydrogen-bonding and hydrophobic 
interactions. This can be achieved by some simple 
chemical modifications of the inhibitor compound. For 
example, introduction of butylpiperazine at the 7-OH 
position of cercosporamide, as shown in Figure 7, would 
appear to favour further contacts with the enzyme, 
involving hydrogen-bonding interactions with Asp228 and 
Lys113. Two further regions that are not involved in direct 
contacts with ATP, but which can be further exploited 
for inhibitor design, are a small hydrophobic pocket 
delineated by the gatekeeper residue Phe159 (hydrophobic Oncotarget 2012; 3:  118-131 127 www.impactjournals.com/oncotarget
I) at the base of the ATP-binding site and the hydrophobic 
region II which opens to the binding cleft. Manipulation 
and  fine  tuning  of  the  structures  by  introducing  the 
appropriate cyclic or acyclic functionalities would create 
an inhibitor that is capable of targeting both the ATP- and 
DFD-binding domains, thus achieving optimal potency 
and specificity. 
CONCLUSIONS
Significant advances have been made in validation 
of the Mnks as potential anti-cancer targets. This is an 
exciting prospect, given their roles in tumour cell biology 
and the fact they are dispensable for animal growth and 
development. The current state of knowledge about the 
structure of these enzymes strongly suggests that design 
of pharmacologic inhibitors that specifically inhibit Mnk 
kinase activity should be achievable. The task ahead is to 
discover inhibitors that not only possess high potency and 
specificity, but also favourable pharmaceutical properties. 
Such inhibitor compounds will serve as chemical biology 
tools for pharmacological target validation in terms of 
Mnk’s role in regulation of Raf/MEK/ERK, PI3K/PTEN/
Akt/mTOR and Jak/STAT pathways in cancers, as well as 
their functions required for normal physiological process. 
A deeper understanding of the biology and structure of 
Mnk would be invaluable in the ongoing discovery and 
development of new and better drugs for cancer treatment.
REFERENCES
1.  Hanahan D and Weinberg RA. Hallmarks of cancer: the 
next generation. Cell. 2011; 144(5):646-674.
2.  Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams 
SL, Franklin RA, Basecke J, Stivala F, Donia M, Fagone 
P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, 
Maksimovic-Ivanic D, Mijatovic S, et al. Ras/Raf/MEK/
ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and 
importance to inhibiting these pathways in human health. 
Oncotarget. 2011; 2(3):135-164.
3.  Petroulakis E, Parsyan A, Dowling RJ, LeBacquer O, 
Martineau Y, Bidinosti M, Larsson O, Alain T, Rong L, 
Mamane Y, Paquet M, Furic L, Topisirovic I, Shahbazian 
D, Livingstone M, Costa-Mattioli M, et al. p53-dependent 
translational control of senescence and transformation via 
4E-BPs. Cancer Cell. 2009; 16(5):439-446.
4.  Hay N and Sonenberg N. Upstream and downstream of 
mTOR. Genes Dev. 2004; 18(16):1926-1945.
5.  Koromilas AE, Lazaris-Karatzas A and Sonenberg N. 
mRNAs containing extensive secondary structure in 
their  5’  non-coding  region  translate  efficiently  in  cells 
overexpressing initiation factor eIF-4E. The EMBO journal. 
1992; 11(11):4153-4158.
6.  Davuluri RV, Suzuki Y, Sugano S and Zhang MQ. CART 
classification of human 5’ UTR sequences. Genome Res. 
2000; 10(11):1807-1816.
7.  van der Velden AW and Thomas AA. The role of the 5’ 
untranslated region of an mRNA in translation regulation 
during development. The international journal of 
biochemistry & cell biology. 1999; 31(1):87-106.
8.  De Benedetti A and Harris AL. eIF4E expression in tumors: 
its possible role in progression of malignancies. The 
international journal of biochemistry & cell biology. 1999; 
31(1):59-72.
9.  Zimmer SG, DeBenedetti A and Graff JR. Translational 
control of malignancy: the mRNA cap-binding protein, 
eIF-4E, as a central regulator of tumor formation, 
growth, invasion and metastasis. Anticancer Res. 2000; 
20(3A):1343-1351.
10.  Kleiner HE, Krishnan P, Tubbs J, Smith M, Meschonat 
C, Shi R, Lowery-Nordberg M, Adegboyega P, Unger M, 
Cardelli J, Chu Q, Mathis JM, Clifford J, De Benedetti A 
and Li BD. Tissue microarray analysis of eIF4E and its 
downstream effector proteins in human breast cancer. J Exp 
Clin Cancer Res. 2009; 28:5.
11.  De Benedetti A and Graff JR. eIF-4E expression and its 
role in malignancies and metastases. Oncogene. 2004; 
23(18):3189-3199.
12. Graff JR and Zimmer SG. Translational control and 
metastatic progression: enhanced activity of the mRNA 
cap-binding protein eIF-4E selectively enhances translation 
of metastasis-related mRNAs. Clin Exp Metastasis. 2003; 
20(3):265-273.
13.  Kerekatte V, Smiley K, Hu B, Smith A, Gelder F and De 
Benedetti A. The proto-oncogene/translation factor eIF4E: a 
survey of its expression in breast carcinomas. International 
journal of cancer Journal international du cancer. 1995; 
64(1):27-31.
14.  Anthony B, Carter P and De Benedetti A. Overexpression 
of the proto-oncogene/translation factor 4E in breast-
carcinoma cell lines. International journal of cancer Journal 
international du cancer. 1996; 65(6):858-863.
15.  Nathan CO, Franklin S, Abreo FW, Nassar R, de Benedetti 
A, Williams J and Stucker FJ. Expression of eIF4E during 
head and neck tumorigenesis: possible role in angiogenesis. 
Laryngoscope. 1999; 109(8):1253-1258.
16.  Rosenwald IB, Chen JJ, Wang S, Savas L, London IM 
and Pullman J. Upregulation of protein synthesis initiation 
factor eIF-4E is an early event during colon carcinogenesis. 
Oncogene. 1999; 18(15):2507-2517.
17.  Wang S, Rosenwald IB, Hutzler MJ, Pihan GA, Savas 
L, Chen JJ and Woda BA. Expression of the eukaryotic 
translation initiation factors 4E and 2alpha in non-
Hodgkin’s lymphomas. The American journal of pathology. 
1999; 155(1):247-255.
18.  Li BD, McDonald JC, Nassar R and De Benedetti A. 
Clinical outcome in stage I to III breast carcinoma and 
eIF4E overexpression. Annals of surgery. 1998; 227(5):756-
756l; discussion 761-753.Oncotarget 2012; 3:  118-131 128 www.impactjournals.com/oncotarget
19.  Rosenwald IB, Hutzler MJ, Wang S, Savas L and Fraire 
AE. Expression of eukaryotic translation initiation factors 
4E and 2alpha is increased frequently in bronchioloalveolar 
but not in squamous cell carcinomas of the lung. Cancer. 
2001; 92(8):2164-2171.
20.  Rosenwald IB, Pechet L, Han A, Lu L, Pihan G, Woda 
B, Chen JJ and Szymanski I. Expression of translation 
initiation factors elF-4E and elF-2alpha and a potential 
physiologic role of continuous protein synthesis in human 
platelets. Thromb Haemost. 2001; 85(1):142-151.
21.  Byrnes K, White S, Chu Q, Meschonat C, Yu H, Johnson 
LW, Debenedetti A, Abreo F, Turnage RH, McDonald JC 
and Li BD. High eIF4E, VEGF, and microvessel density 
in stage I to III breast cancer. Annals of surgery. 2006; 
243(5):684-690; discussion 691-682.
22.  Clemens MJ and Bommer UA. Translational control: the 
cancer connection. The international journal of biochemistry 
& cell biology. 1999; 31(1):1-23.
23.  De Benedetti A, Joshi-Barve S, Rinker-Schaeffer C and 
Rhoads RE. Expression of antisense RNA against initiation 
factor eIF-4E mRNA in HeLa cells results in lengthened 
cell division times, diminished translation rates, and 
reduced levels of both eIF-4E and the p220 component of 
eIF-4F. Molecular and cellular biology. 1991; 11(11):5435-
5445.
24.  Graff JR, Boghaert ER, De Benedetti A, Tudor DL, Zimmer 
CC, Chan SK and Zimmer SG. Reduction of translation 
initiation factor 4E decreases the malignancy of ras-
transformed cloned rat embryo fibroblasts. International 
journal of cancer Journal international du cancer. 1995; 
60(2):255-263.
25.  Rinker-Schaeffer CW, Graff JR, De Benedetti A, Zimmer 
SG and Rhoads RE. Decreasing the level of translation 
initiation factor 4E with antisense RNA causes reversal of 
ras-mediated transformation and tumorigenesis of cloned rat 
embryo fibroblasts. International journal of cancer Journal 
international du cancer. 1993; 55(5):841-847.
26.  Nathan CO, Liu L, Li BD, Abreo FW, Nandy I and De 
Benedetti A. Detection of the proto-oncogene eIF4E in 
surgical margins may predict recurrence in head and neck 
cancer. Oncogene. 1997; 15(5):579-584.
27.  Nathan CO, Carter P, Liu L, Li BD, Abreo F, Tudor A, 
Zimmer SG and De Benedetti A. Elevated expression of 
eIF4E and FGF-2 isoforms during vascularization of breast 
carcinomas. Oncogene. 1997; 15(9):1087-1094.
28.  DeFatta RJ, Nathan CO and De Benedetti A. Antisense 
RNA to eIF4E suppresses oncogenic properties of a head 
and neck squamous cell carcinoma cell line. Laryngoscope. 
2000; 110(6):928-933.
29.  Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri FR and Sun 
SY. Phosphorylated eukaryotic translation initiation factor 
4 (eIF4E) is elevated in human cancer tissues. Cancer Biol 
Ther. 2009; 8(15):1463-1469.
30.  Wendel H-G, de Stanchina E, Fridman JS, Malina A, Ray 
S, Kogan S, Cordon-Cardo C, Pelletier J and Lowe SW. 
Survival signalling by Akt and eIF4E in oncogenesis and 
cancer therapy. Nature. 2004; 428(6980):332-337.
31. Sonenberg N and Hinnebusch AG. New modes of 
translational control in development, behavior, and disease. 
Molecular cell. 2007; 28(5):721-729.
32.  Raught B and Gingras AC. eIF4E activity is regulated at 
multiple levels. The international journal of biochemistry 
& cell biology. 1999; 31(1):43-57.
33.  Gingras AC, Raught B and Sonenberg N. eIF4 initiation 
factors: effectors of mRNA recruitment to ribosomes and 
regulators of translation. Annual Review of Biochemistry. 
1999; 68:913-963.
34. Pestova TV, Kolupaeva VG, Lomakin IB, Pilipenko 
EV, Shatsky IN, Agol VI and Hellen CU. Molecular 
mechanisms of translation initiation in eukaryotes. Proc 
Natl Acad Sci U S A. 2001; 98(13):7029-7036.
35.  Hay N. Mnk earmarks eIF4E for cancer therapy. Proc Natl 
Acad Sci U S A. 2010; 107(32):13975-13976.
36.  Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf 
CR, Basecke J, Stivala F, Donia M, Fagone P, Nicoletti 
F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli 
AM and McCubrey JA. Roles of the Ras/Raf/MEK/ERK 
pathway in leukemia therapy. Leukemia : official journal 
of the Leukemia Society of America, Leukemia Research 
Fund, UK. 2011; 25(7):1080-1094.
37.  McCubrey JA, Steelman LS, Kempf CR, Chappell WH, 
Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, 
Basecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto 
G, Cervello M, Cocco L and Martelli AM. Therapeutic 
resistance resulting from mutations in Raf/MEK/ERK and 
PI3K/PTEN/Akt/mTOR signaling pathways. Journal of 
cellular physiology. 2011; 226(11):2762-2781.
38.  Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, Misri 
S, Zeng S, Pagan J, Jeffery J, Puc J, Kumar R, Feng Z, 
Powell SN, Bhat A, Yaguchi T, Wadhwa R, et al. Cell 
cycle checkpoint defects contribute to genomic instability 
in PTEN deficient cells independent of DNA DSB repair. 
Cell Cycle. 2009; 8(14):2198-2210.
39.  Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, 
Meric-Bernstam F, Hennessy BT, Craven RJ and Lin SY. 
Rak functions as a tumor suppressor by regulating PTEN 
protein stability and function. Cancer Cell. 2009; 15(4):304-
314.
40. Duncan R, Milburn SC and Hershey JW. Regulated 
phosphorylation and low abundance of HeLa cell initiation 
factor eIF-4F suggest a role in translational control. Heat 
shock effects on eIF-4F. J Biol Chem. 1987; 262(1):380-
388.
41.  Sonenberg N. eIF4E, the mRNA cap-binding protein: from 
basic discovery to translational research. Biochem Cell 
Biol. 2008; 86(2):178-183.
42.  Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, 
Taunton J, Hershey JW, Blenis J, Pende M and Sonenberg Oncotarget 2012; 3:  118-131 129 www.impactjournals.com/oncotarget
N. The mTOR/PI3K and MAPK pathways converge on 
eIF4B to control its phosphorylation and activity. The 
EMBO journal. 2006; 25(12):2781-2791.
43.  Brachmann S, Fritsch C, Maira SM and Garcia-Echeverria 
C. PI3K and mTOR inhibitors: a new generation of targeted 
anticancer agents. Current opinion in cell biology. 2009; 
21(2):194-198.
44.  LoPiccolo J, Blumenthal GM, Bernstein WB and Dennis 
PA. Targeting the PI3K/Akt/mTOR pathway: effective 
combinations and clinical considerations. Drug resistance 
updates : reviews and commentaries in antimicrobial and 
anticancer chemotherapy. 2008; 11(1-2):32-50.
45.  Meric-Bernstam F and Gonzalez-Angulo AM. Targeting 
the mTOR signaling network for cancer therapy. Journal of 
clinical oncology : official journal of the American Society 
of Clinical Oncology. 2009; 27(13):2278-2287.
46.  Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, 
Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J 
and Thomas G. Absence of S6K1 protects against age- and 
diet-induced obesity while enhancing insulin sensitivity. 
Nature. 2004; 431(7005):200-205.
47. Harrington LS, Findlay GM, Gray A, Tolkacheva T, 
Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, 
Shepherd PR, Gout I, Downes CP and Lamb RF. The 
TSC1-2 tumor suppressor controls insulin-PI3K signaling 
via regulation of IRS proteins. The Journal of cell biology. 
2004; 166(2):213-223.
48.  Costa F and F JB. [Treatment of non-small cell lung cancer 
in elderly patients]. Rev Port Pneumol. 2007; 13(6):841-
854.
49.  Scheper GC, van Kollenburg B, Hu J, Luo Y, Goss DJ and 
Proud CG. Phosphorylation of eukaryotic initiation factor 
4E markedly reduces its affinity for capped mRNA. The 
Journal of biological chemistry. 2002; 277(5):3303-3309.
50.  Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis 
JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, 
Lazar AJ, Pollock RE and Lev D. Dual targeting of AKT 
and mammalian target of rapamycin: a potential therapeutic 
approach for malignant peripheral nerve sheath tumor. 
Molecular Cancer Therapeutics. 2009; 8(5):1157-1168.
51.  Wang X, Yue P, Chan CB, Ye K, Ueda T, Watanabe-
Fukunaga R, Fukunaga R, Fu H, Khuri FR and Sun SY. 
Inhibition of mammalian target of rapamycin induces 
phosphatidylinositol 3-kinase-dependent and Mnk-mediated 
eukaryotic translation initiation factor 4E phosphorylation. 
Mol Cell Biol. 2007; 27(21):7405-7413.
52.  Scheper GC and Proud CG. Does phosphorylation of 
the cap-binding protein eIF4E play a role in translation 
initiation? Eur J Biochem. 2002; 269(22):5350-5359.
53.  Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S and 
Fukunaga R. Mnk2 and Mnk1 are essential for constitutive 
and inducible phosphorylation of eukaryotic initiation factor 
4E but not for cell growth or development. Mol Cell Biol. 
2004; 24(15):6539-6549.
54.  Ueda T, Sasaki M, Elia AJ, Chio, II, Hamada K, Fukunaga 
R and Mak TW. Combined deficiency for MAP kinase-
interacting kinase 1 and 2 (Mnk1 and Mnk2) delays 
tumor development. Proc Natl Acad Sci U S A. 2010; 
107(32):13984-13990.
55.  Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida 
K, Brueschke A, Petroulakis E, Robichaud N, Pollak 
M, Gaboury LA, Pandolfi PP, Saad F and Sonenberg N. 
eIF4E phosphorylation promotes tumorigenesis and is 
associated with prostate cancer progression. Proceedings of 
the National Academy of Sciences of the United States of 
America. 2010; 107(32):14134-14139.
56.  Waskiewicz AJ, Flynn A, Proud CG and Cooper JA. 
Mitogen-activated protein kinases activate the serine/
threonine kinases Mnk1 and Mnk2. EMBO J. 1997; 
16(8):1909-1920.
57.  Fukunaga R and Hunter T. MNK1, a new MAP kinase-
activated protein kinase, isolated by a novel expression 
screening method for identifying protein kinase substrates. 
EMBO J. 1997; 16(8):1921-1933.
58.  O’Loghlen A, Gonzalez VM, Pineiro D, Perez-Morgado 
MI, Salinas M and Martin ME. Identification and molecular 
characterization of Mnk1b, a splice variant of human MAP 
kinase-interacting kinase Mnk1. Experimental cell research. 
2004; 299(2):343-355.
59.  Scheper GC, Parra JL, Wilson M, Van Kollenburg B, 
Vertegaal AC, Han ZG and Proud CG. The N and C termini 
of the splice variants of the human mitogen-activated 
protein kinase-interacting kinase Mnk2 determine activity 
and localization. Molecular and cellular biology. 2003; 
23(16):5692-5705.
60.  Scheper GC, Morrice NA, Kleijn M and Proud CG. The 
mitogen-activated protein kinase signal-integrating kinase 
Mnk2 is a eukaryotic initiation factor 4E kinase with high 
levels of basal activity in mammalian cells. Molecular and 
cellular biology. 2001; 21(3):743-754.
61.  Jauch R, Jakel S, Netter C, Schreiter K, Aicher B, Jackle 
H and Wahl MC. Crystal structures of the Mnk2 kinase 
domain reveal an inhibitory conformation and a zinc 
binding site. Structure. 2005; 13(10):1559-1568.
62.  O’Loghlen A, Gonzalez VM, Jurado T, Salinas M and 
Martin ME. Characterization of the activity of human MAP 
kinase-interacting kinase Mnk1b. Biochimica et biophysica 
acta. 2007; 1773(9):1416-1427.
63.  Ben-Levy R, Leighton IA, Doza YN, Attwood P, Morrice 
N,  Marshall  CJ  and  Cohen  P.  Identification  of  novel 
phosphorylation sites required for activation of MAPKAP 
kinase-2. The EMBO journal. 1995; 14(23):5920-5930.
64.  Parra-Palau JL, Scheper GC, Wilson ML and Proud CG. 
Features in the N and C termini of the MAPK-interacting 
kinase Mnk1 mediate its nucleocytoplasmic shuttling. The 
Journal of biological chemistry. 2003; 278(45):44197-
44204.
65.  Buxade M, Parra-Palau JL and Proud CG. The Mnks: MAP Oncotarget 2012; 3:  118-131 130 www.impactjournals.com/oncotarget
kinase-interacting kinases (MAP kinase signal-integrating 
kinases). Front Biosci. 2008; 13:5359-5373.
66.  Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T 
and Sonenberg N. Human eukaryotic translation initiation 
factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. 
The EMBO journal. 1999; 18(1):270-279.
67.  Flynn A and Proud CG. Serine 209, not serine 53, is the 
major site of phosphorylation in initiation factor eIF-4E in 
serum-treated Chinese hamster ovary cells. The Journal of 
biological chemistry. 1995; 270(37):21684-21688.
68.  Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez 
M and Borden KL. eIF4E is a central node of an RNA 
regulon that governs cellular proliferation. The Journal of 
cell biology. 2006; 175(3):415-426.
69. Topisirovic I, Ruiz-Gutierrez M and Borden KL. 
Phosphorylation of the eukaryotic translation initiation 
factor eIF4E contributes to its transformation and mRNA 
transport activities. Cancer research. 2004; 64(23):8639-
8642.
70. Phillips A and Blaydes JP. MNK1 and EIF4E are 
downstream effectors of MEKs in the regulation of 
the nuclear export of HDM2 mRNA. Oncogene. 2008; 
27(11):1645-1649.
71.  Lachance PE, Miron M, Raught B, Sonenberg N and Lasko 
P. Phosphorylation of eukaryotic translation initiation factor 
4E is critical for growth. Molecular and cellular biology. 
2002; 22(6):1656-1663.
72.  Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda 
T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein 
J, Pelletier J and Lowe SW. Dissecting eIF4E action in 
tumorigenesis. Genes Dev. 2007; 21(24):3232-3237.
73.  Wang X, Beugnet A, Murakami M, Yamanaka S and 
Proud CG. Distinct signaling events downstream of mTOR 
cooperate to mediate the effects of amino acids and insulin 
on initiation factor 4E-binding proteins. Molecular and 
cellular biology. 2005; 25(7):2558-2572.
74.  Choo AY, Yoon SO, Kim SG, Roux PP and Blenis J. 
Rapamycin differentially inhibits S6Ks and 4E-BP1 to 
mediate cell-type-specific repression of mRNA translation. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2008; 105(45):17414-17419.
75.  Tschopp C, Knauf U, Brauchle M, Zurini M, Ramage P, 
Glueck D, New L, Han J and Gram H. Phosphorylation 
of eIF-4E on Ser 209 in response to mitogenic and 
inflammatory  stimuli  is  faithfully  detected  by  specific 
antibodies. Mol Cell Biol Res Commun. 2000; 3(4):205-
211.
76.  Chrestensen CA, Shuman JK, Eschenroeder A, Worthington 
M, Gram H and Sturgill TW. MNK1 and MNK2 regulation 
in HER2-overexpressing breast cancer lines. J Biol Chem. 
2007; 282(7):4243-4252.
77.  Buxade M, Parra JL, Rousseau S, Shpiro N, Marquez R, 
Morrice N, Bain J, Espel E and Proud CG. The Mnks are 
novel components in the control of TNF alpha biosynthesis 
and phosphorylate and regulate hnRNP A1. Immunity. 
2005; 23(2):177-189.
78.  Worch J, Tickenbrock L, Schwable J, Steffen B, Cauvet 
T, Mlody B, Buerger H, Koeffler HP, Berdel WE, Serve H 
and Muller-Tidow C. The serine-threonine kinase MNK1 
is post-translationally stabilized by PML-RARalpha and 
regulates differentiation of hematopoietic cells. Oncogene. 
2004; 23(57):9162-9172.
79.  Rowlett RM, Chrestensen CA, Nyce M, Harp MG, Pelo 
JW, Cominelli F, Ernst PB, Pizarro TT, Sturgill TW 
and Worthington MT. MNK kinases regulate multiple 
TLR pathways and innate proinflammatory cytokines in 
macrophages. Am J Physiol Gastrointest Liver Physiol. 
2008; 294(2):G452-459.
80.  Konicek BW, Stephens JR, McNulty AM, Robichaud N, 
Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons 
S, Ellis KE, McCann DJ, Pelletier J, Furic L, Yingling JM, 
Stancato LF, Sonenberg N, et al. Therapeutic inhibition of 
MAP kinase interacting kinase blocks eukaryotic initiation 
factor 4E phosphorylation and suppresses outgrowth 
of experimental lung metastases. Cancer Res. 2011; 
71(5):1849-1857.
81.  Knauf U, Tschopp C and Gram H. Negative regulation 
of protein translation by mitogen-activated protein 
kinase-interacting kinases 1 and 2. Mol Cell Biol. 2001; 
21(16):5500-5511.
82.  Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan 
H, Klevernic I, Arthur JS, Alessi DR and Cohen P. The 
selectivity of protein kinase inhibitors: a further update. The 
Biochemical journal. 2007; 408(3):297-315.
83.  Chrestensen CA, Eschenroeder A, Ross WG, Ueda T, 
Watanabe-Fukunaga R, Fukunaga R and Sturgill TW. Loss 
of MNK function sensitizes fibroblasts to serum-withdrawal 
induced apoptosis. Genes to cells : devoted to molecular & 
cellular mechanisms. 2007; 12(10):1133-1140.
84.  Li Y, Yue P, Deng X, Ueda T, Fukunaga R, Khuri FR 
and Sun SY. Protein phosphatase 2A negatively regulates 
eukaryotic initiation factor 4E phosphorylation and eIF4F 
assembly through direct dephosphorylation of Mnk and 
eIF4E. Neoplasia. 2010; 12(10):848-855.
85.  Sussman A, Huss K, Chio LC, Heidler S, Shaw M, Ma D, 
Zhu G, Campbell RM, Park TS, Kulanthaivel P, Scott JE, 
Carpenter JW, Strege MA, Belvo MD, Swartling JR, Fischl 
A, et al. Discovery of cercosporamide, a known antifungal 
natural product, as a selective Pkc1 kinase inhibitor through 
high-throughput screening. Eukaryotic cell. 2004; 3(4):932-
943.
86.  Hong Z, Mann P, Brown NH, Tran LE, Shaw KJ, Hare 
RS and DiDomenico B. Cloning and characterization of 
KNR4, a yeast gene involved in (1,3)-beta-glucan synthesis. 
Molecular and cellular biology. 1994; 14(2):1017-1025.
87.  Singh MP, Leighton MM, Barbieri LR, Roll DM, Urbance 
SE, Hoshan L and McDonald LA. Fermentative production 
of self-toxic fungal secondary metabolites. J Ind Microbiol 
Biotechnol. 2010; 37(4):335-340.Oncotarget 2012; 3:  118-131 131 www.impactjournals.com/oncotarget
88.  Roux PP and Blenis J. ERK and p38 MAPK-activated 
protein kinases: a family of protein kinases with diverse 
biological functions. Microbiol Mol Biol Rev. 2004; 
68(2):320-344.
89.  Jauch R, Cho MK, Jakel S, Netter C, Schreiter K, Aicher B, 
Zweckstetter M, Jackle H and Wahl MC. Mitogen-activated 
protein kinases interacting kinases are autoinhibited by 
a reprogrammed activation segment. EMBO J. 2006; 
25(17):4020-4032.
90.  Goto S, Yao Z and Proud CG. The C-terminal domain of 
Mnk1a plays a dual role in tightly regulating its activity. 
Biochem J. 2009; 423(2):279-290.
91.  Liu Y and Gray NS. Rational design of inhibitors that bind 
to inactive kinase conformations. Nat Chem Biol. 2006; 
2(7):358-364.
92.  Cohen MS, Zhang C, Shokat KM and Taunton J. Structural 
bioinformatics-based design of selective, irreversible kinase 
inhibitors. Science. 2005; 308(5726):1318-1321.
93.  Noble MEM, Endicott JA and Johnson LN. Protein Kinase 
Inhibitors: Insights into Drug Design from Structure. 
Science. 2004; 303(5665):1800-1805.
94.  Wang S, Griffiths G, Midgley CA, Barnett AL, Cooper M, 
Grabarek J, Ingram L, Jackson W, Kontopidis G, McClue 
SJ, McInnes C, McLachlan J, Meades C, Mezna M, Stuart 
I, Thomas MP, et al. Discovery and characterization of 
2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK 
inhibitors as anticancer agents. Chemistry & biology. 2010; 
17(10):1111-1121.
95. Wang S and Fischer PM. Cyclin-dependent kinase 
9: a key transcriptional regulator and potential drug 
target in oncology, virology and cardiology. Trends in 
pharmacological sciences. 2008; 29(6):302-313.
96.  Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, 
Graham AG, Grob PM, Hickey ER, Moss N, Pav S and 
Regan J. Inhibition of p38 MAP kinase by utilizing a novel 
allosteric binding site. Nature Structural Biology. 2002; 
9(4):268-272.